Sign in
Taking people in United StatesPhase 2

Adds dasatinib or venetoclax to chemotherapy in children with T-cell leukemia or lymphoma

Tests adding dasatinib or venetoclax to chemotherapy in children with new T-cell leukemia.

Key facts

Who runs it
St. Jude Children's Research Hospital
Where
Charlotte, Memphis, San Diego, and Tulsa, United StatesSee the 4 sites
Trial code
Registry title
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
Status
Recruiting
Phase
Phase 2
People taking part
100 people, planned
Started
27 Dec 2024
Expected to end
Dec 2033
Type of study
Interventional, 3 groups
Treatments tested
  • Dexamethasone
  • Vincristine
  • Daunorubicin
  • Calaspargase pegol
  • Dasatinib
  • Venetoclax
  • Bortezomib
  • Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)
  • Cyclophosphamide
  • Cytarabine
  • Mercaptopurine
  • Nelarabine
  • Methotrexate
  • Thioguanine
Record updated
10 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young people with newly diagnosed T-cell acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia or lymphoma. They must also be enrolled on INITIALL.

Age
1 to 18.99 years at enrollment on INITIALL.
Sex
All sexes can join.
Disease stage
Newly diagnosed T-cell acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia or lymphoma.
Earlier treatment
No earlier chemotherapy, except treatment given on or allowed by INITIALL. No more than 3 days of chemotherapy on INITIALL.

Main reasons for not taking part

  • Known HIV infection, active hepatitis B or hepatitis C
  • Pregnant or breastfeeding
  • More than grade 2 neuropathy (people with T-LLy only)
  • A condition that stops oral medicines from being taken, such as malabsorption syndrome
  • Strong or moderate CYP3A4 inducer drugs within 7 days of starting treatment

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Enrollment on INITIALL
  • Age 1-18.99 years at the time of enrollment on INITIALL
  • T-Acute lymphoblastic leukemia or lymphoblastic lymphoma or mixed phenotype acute leukemia/ lymphoma
  • No prior chemotherapy excluding therapy given on or allowed by INITIALL
  • Patient has completed no more than 3 days of chemotherapy on INITIALL
  • Direct bilirubin ≤ 1.5x the upper limit of normal for age
  • Alanine aminotransferase (ALT) ≤ 5x the upper limit of normal for age
  • Calculated glomerular filtration rate (GFR) ≥ 50 mL/min/1.73m\^2 using the Bedside Schwartz equation OR creatinine below or equal to the maximum defined below:; Age: 1 to < 2 years - Maximum serum creatinine (mg/dL): 0.6 (Male), 0.6 (Female); Age: 2 to < 6 years - Maximum serum creatinine (mg/dL): 0.8 (Male), 0.8 (Female); Age: 6 to < 10 years - Maximum serum creatinine (mg/dL): 1 (Male), 1 (Female); Age: 10 to < 13 years - Maximum serum creatinine (mg/dL): 1.2 (Male), 1.2 (Female); Age: 13 to < 16 years - - Maximum serum creatinine (mg/dL): 1.5 (Male), 1.4 (Female); Age: ≥ 16 years - Maximum serum creatinine (mg/dL): 1.7 (Male), 1.4 (Female)

Who cannot take part

  • For patients of reproductive potential, unwillingness to use highly effective contraception for the duration of protocol therapy and for 90 days afterwards
  • Consumption of grapefruit, grapefruit products, Seville oranges, or starfruit within 3 days of the start of protocol therapy
  • Documented malabsorption syndrome or any other condition that precludes receipt of oral medications
  • Known HIV infection or active hepatitis B (defined as hepatitis B surface antigen-positive) or C (defined as hepatitis C antibody-positive)
  • Inability or unwillingness to give informed consent/ assent as applicable
  • Patients with > Grade 2 neuropathy at the time of enrollment (participant with T-LLy only)
  • Pregnant or lactating
  • Receipt of a strong or moderate CYP3A4 inducer such as rifampin, carbamazepine, phenytoin, and St. John's wort within 7 days of the start of protocol treatment

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 1 and 18 years old?

Where in United States

  • Novant Health Presbyterian Hemby Children's HospitalCharlotte, United StatesContact: Jessica Bell, MDTaking people
  • St. Jude Children's Research HospitalMemphis, United StatesContact: Seth E. Karol, MD, MSCITaking people
  • Rady Children's HospitalSan Diego, United StatesContact: Victor Wong, MDTaking people
  • Saint Francis Children's HospitalTulsa, United StatesContact: Ashraf Mohamed, MDTaking people

About the trial

What the trial wants to find out

This is a clinical trial testing whether the addition of one of two chemotherapy agents, dasatinib or venetoclax, can improve outcomes for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma or mixed phenotype acute leukemia.

Read full original descriptionShow less

Primary Objective

* To evaluate if the end of induction MRD-negative rate is higher in patients with T-ALL treated with dasatinib compared to similar patients treated with 4-drug induction on AALL1231. * To evaluate if the end of induction MRD-negative rate is higher in patients with ETP or near-ETP ALL treated with venetoclax compared to similar patients treated with 4-drug induction on AALL1231.

Secondary Objectives

* To assess the event free and overall survival of patients treated with this therapy. * To compare grade 4 toxicities, event-free survival (EFS) and overall survival (OS) of patients treated with this therapy in induction and reinduction to toxicities of similar patients treated on TOT17.

The 3 groups in the trial

  • Patients with T-ALL (except ETP or near-ETP)Treatment being tested

    All eligible patients receive intervention according to the Detailed Description section with the following: Induction: Dexamethasone, Vincristine, Daunorubicin, Calaspargase pegol, Dasatinib, IT MHA Early Post Induction: Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, IT MHA, Methotrexate, Dasatinib, Dexamethasone, Vincristine, Daunorubicin, Calaspargase pegol Maintenance: Mercaptopurine, Methotrexate, Nelarabine, Cyclophosphamide, Cytarabine, Dexamethasone, Vincristine, Dasatinib, IT MHA, Thioguanine

    Treatment: Dexamethasone, Vincristine, Daunorubicin, Calaspargase pegol, Dasatinib, Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine), Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Methotrexate, and Thioguanine

  • Patients with ETP or near-ETP ALL or MPALTreatment being tested

    All eligible patients receive intervention according to the Detailed Description section with the following: Induction: Dexamethasone, Vincristine, Daunorubicin, Calaspargase pegol, Venetoclax, IT MHA Early Post Induction: Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, IT MHA, Methotrexate, Dexamethasone, Vincristine, Daunorubicin, Calaspargase pegol, Venetoclax Maintenance: Mercaptopurine, Methotrexate, Nelarabine, Cyclophosphamide, Cytarabine, Dexamethasone, Vincristine, IT MHA, Thioguanine

    Treatment: Dexamethasone, Vincristine, Daunorubicin, Calaspargase pegol, Venetoclax, Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine), Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Methotrexate, and Thioguanine

  • Patients with T-LLyTreatment being tested

    All eligible patients receive intervention according to the Detailed Description section with the following: Induction: Dexamethasone, Vincristine, Daunorubicin, Calaspargase pegol, Bortezomib, IT MHA Early Post Induction: Cyclophosphamide, Cytarabine, Mercaptopurine, IT MHA, Methotrexate, Dexamethasone, Vincristine, Daunorubicin, Calaspargase pegol, Bortezomib Maintenance: Mercaptopurine, Methotrexate, Cyclophosphamide, Cytarabine, Dexamethasone, Vincristine, IT MHA, Thioguanine

    Treatment: Dexamethasone, Vincristine, Daunorubicin, Calaspargase pegol, Bortezomib, Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine), Cyclophosphamide, Cytarabine, Mercaptopurine, Methotrexate, and Thioguanine

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
SJALL23T: Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
Plain-language title
Adds dasatinib or venetoclax to chemotherapy in children with T-cell leukemia or lymphomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06390319, who can take part
Publications
Record updated
10 August 2026